HOBOKEN, NJ —Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation and learning, today released the Wiley Registry of Mass Spectral Data 2026 .
As AI-driven research pipelines become standard practice across pharmaceuticals, materials science and forensic investigation, the quality of reference data underpinning those pipelines determines whether results are trusted—or stall at the verification stage.
The Wiley Registry of Mass Spectral Data 2026 addresses this issue directly: One of the world’s largest and most trusted mass spectral reference databases for identifying unknown chemical compounds, it is now expanded and validated to meet the analytical demands of modern, AI-assisted laboratory workflows.
Laboratories face increasingly complex analytical challenges—from detecting emerging environmental contaminants to identifying novel substances in forensic investigations. As a result, having access to a comprehensive, rigorously validated spectral database has become foundational to getting results right. It is also a critical validation layer for AI-driven workflows.
The Wiley Registry database helps scientists and researchers around the world with environmental testing, forensic investigation, food safety research, drug analysis, defense research, homeland security, and more, providing critical reference data for identifying and analyzing chemical compounds and materials.
The new edition represents a significant expansion of the collection, which now contains more than 915,500 reference spectra—the unique chemical “signatures” used to identify substances—making it among the most comprehensive databases of its kind. More than 42,000 new GC-MS spectra representing 34,100 compounds have been added, with data from laboratories, world patents and peer-reviewed scientific literature. Each spectrum is validated to the same rigorous standard, ensuring that the data perform reliably whether a researcher is running a manual comparison or feeding it into an automated identification pipeline.
The Wiley Registry is part of Wiley’s growing portfolio of scientific data and research intelligence solutions, which includes spectral databases, chemistry and materials literature, and analytical tools designed to support researchers and organizations from discovery through to applied outcomes. Wiley spectral database solutions are trusted by the world’s top pharmaceutical companies and many Fortune 500 organizations—reflecting Wiley’s mission to transform knowledge into actionable intelligence, equipping researchers with the rigorous reference data that drives real-world scientific discovery.
Updated every three years, the Wiley Registry is among the company’s longest-standing data products, with a history spanning decades of continuous development.
“The Wiley Registry is a foundational layer of intelligence for any laboratory conducting GC-MS analysis—and increasingly, for the AI-assisted workflows being built around that analysis,” said Armughan Rafat, Wiley senior vice president and chief AI & data analytics officer. “By expanding compound coverage and applying consistent quality measures across the collection, we help analysts provide a deterministic layer to move from unknown to identified faster.”
Available in the most common instrumentation manufacturer formats, the Wiley Registry of Mass Spectral Data 2026 also offers bundled options to access even more data with its Wiley Registry/NIST and the KnowItAll GC-MS Library collection for labs seeking the most comprehensive coverage and workflow integration. The Wiley Registry is also available as a KnowItAll subscription for continued access to new data as they are added to the collection.
Spectral databases contain detailed “fingerprints” of substances captured through analytical techniques such as mass spectrometry (MS) or Raman spectroscopy, enabling researchers to identify unknown materials by comparing their spectral signatures against validated reference spectra. This data is essential for quality control, research verification and discovery across industries from pharmaceuticals to materials science.
For more information about the Wiley Registry of Mass Spectral Data 2026 , please visit: https://sciencesolutions.wiley.com/solutions/technique/gc-ms/wiley-registry-of-mass-spectral-data/
To learn more about Wiley’s broader scientific data and research intelligence offering, visit www.wiley.com.
About Wiley
Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.
Media Contact : newsroom@wiley.com